196 related articles for article (PubMed ID: 37407689)
21. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
[No Abstract] [Full Text] [Related]
22. Netrin-1 elicits metastatic potential of non-small cell lung carcinoma cell by enhancing cell invasion, migration and vasculogenic mimicry via EMT induction.
Zhang X; Cui P; Ding B; Guo Y; Han K; Li J; Chen H; Zhang W
Cancer Gene Ther; 2018 Feb; 25(1-2):18-26. PubMed ID: 29234153
[TBL] [Abstract][Full Text] [Related]
23. HIF-1α promoted vasculogenic mimicry formation in lung adenocarcinoma through NRP1 upregulation in the hypoxic tumor microenvironment.
Fu R; Du W; Ding Z; Wang Y; Li Y; Zhu J; Zeng Y; Zheng Y; Liu Z; Huang JA
Cell Death Dis; 2021 Apr; 12(4):394. PubMed ID: 33850110
[TBL] [Abstract][Full Text] [Related]
24. Predictive biomarkers for immunotherapy efficacy in non-small-cell lung cancer: current status and future perspectives.
Guven DC; Sahin TK; Dizdar O; Kilickap S
Biomark Med; 2020 Oct; 14(14):1383-1392. PubMed ID: 33064030
[TBL] [Abstract][Full Text] [Related]
25. Dual Specificity Phosphatase 6 (DUSP6) Polymorphism Predicts Prognosis of Inoperable Non-Small Cell Lung Cancer after Chemoradiotherapy.
Wang TL; Song YQ; Ren YW; Zhou BS; Wang HT; Bai L; Zhang HB; Yu H; Zhao YX
Clin Lab; 2016; 62(3):301-10. PubMed ID: 27156317
[TBL] [Abstract][Full Text] [Related]
26. Overexpression of S100A13 protein is associated with tumor angiogenesis and poor survival in patients with early-stage non-small cell lung cancer.
Miao S; Qiu T; Zhao Y; Wang H; Sun X; Wang Y; Xuan Y; Qin Y; Jiao W
Thorac Cancer; 2018 Sep; 9(9):1136-1144. PubMed ID: 30047626
[TBL] [Abstract][Full Text] [Related]
27. Integrative Analysis of m6A RNA Methylation Regulators and the Tumor Immune Microenvironment in Non-Small-Cell Lung Cancer.
Zhu J; Jiang Y; Wang T; Wu A; Zhou T; Zhang A; Tang Y; Shen Z; Wang J; Zhou H; Shi J; Chen J
Dis Markers; 2022; 2022():2989200. PubMed ID: 35186164
[TBL] [Abstract][Full Text] [Related]
28. Current Immunotherapeutic Strategies Targeting the PD-1/PD-L1 Axis in Non-Small Cell Lung Cancer with Oncogenic Driver Mutations.
Tanaka I; Morise M
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008669
[TBL] [Abstract][Full Text] [Related]
29. Immunotherapy checkpoints in ovarian cancer vasculogenic mimicry: Tumor immune microenvironments, and drugs.
Hu H; Ma T; Liu N; Hong H; Yu L; Lyu D; Meng X; Wang B; Jiang X
Int Immunopharmacol; 2022 Oct; 111():109116. PubMed ID: 35969899
[TBL] [Abstract][Full Text] [Related]
30. M6A regulator expression patterns predict the immune microenvironment and prognosis of non-small cell lung cancer.
Liu X; Ma C; Liu H; Sun Z; Luo J
J Cancer Res Clin Oncol; 2022 Oct; 148(10):2803-2814. PubMed ID: 35596010
[TBL] [Abstract][Full Text] [Related]
31. Machine learning reveals a PD-L1-independent prediction of response to immunotherapy of non-small cell lung cancer by gene expression context.
Wiesweg M; Mairinger F; Reis H; Goetz M; Kollmeier J; Misch D; Stephan-Falkenau S; Mairinger T; Walter RFH; Hager T; Metzenmacher M; Eberhardt WEE; Zaun G; Köster J; Stuschke M; Aigner C; Darwiche K; Schmid KW; Rahmann S; Schuler M
Eur J Cancer; 2020 Nov; 140():76-85. PubMed ID: 33059196
[TBL] [Abstract][Full Text] [Related]
32. Genomic and transcriptional alterations in first-line chemotherapy exert a potentially unfavorable influence on subsequent immunotherapy in NSCLC.
He Y; Chen L; Zhao L; Dang S; Liu G; Sasada S; Ma PC; van Zandwijk N; Rosell R; Popper HH; Wang H; Jiang M; Guo H; Liu X; Chen S; Zhang X; Xu M; Zhu B; Liu M; Zhou C
Theranostics; 2021; 11(14):7092-7109. PubMed ID: 34093873
[No Abstract] [Full Text] [Related]
33. KAT2B is an immune infiltration-associated biomarker predicting prognosis and response to immunotherapy in non-small cell lung cancer.
Zhou X; Wang N; Zhang Y; Yu H; Wu Q
Invest New Drugs; 2022 Feb; 40(1):43-57. PubMed ID: 34499335
[TBL] [Abstract][Full Text] [Related]
34. Vasculogenic mimicry in carcinogenesis and clinical applications.
Luo Q; Wang J; Zhao W; Peng Z; Liu X; Li B; Zhang H; Shan B; Zhang C; Duan C
J Hematol Oncol; 2020 Mar; 13(1):19. PubMed ID: 32169087
[TBL] [Abstract][Full Text] [Related]
35. Construction of a B cell-related gene pairs signature for predicting prognosis and immunotherapeutic response in non-small cell lung cancer.
Li X; Wang R; Wang S; Wang L; Yu J
Front Immunol; 2022; 13():989968. PubMed ID: 36389757
[TBL] [Abstract][Full Text] [Related]
36. Immune checkpoints related-LncRNAs can identify different subtypes of lung cancer and predict immunotherapy and prognosis.
Zhang H; Liu M; Du G; Yu B; Ma X; Gui Y; Cao L; Li X; Tan B
J Cancer Res Clin Oncol; 2022 Jul; 148(7):1597-1612. PubMed ID: 35296921
[TBL] [Abstract][Full Text] [Related]
37. The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers.
Takada K; Toyokawa G; Shoji F; Okamoto T; Maehara Y
Clin Lung Cancer; 2018 Mar; 19(2):120-129. PubMed ID: 29153898
[TBL] [Abstract][Full Text] [Related]
38. [Immunotherapy in Epidermal Growth Factor Receptor-mutant
Non-small Cell Lung Cancer].
Wang X; Zhong D
Zhongguo Fei Ai Za Zhi; 2019 Aug; 22(8):541-545. PubMed ID: 31451147
[TBL] [Abstract][Full Text] [Related]
39. PD-L1 and PD-L2 expression correlated genes in non-small-cell lung cancer.
Larsen TV; Hussmann D; Nielsen AL
Cancer Commun (Lond); 2019 Jun; 39(1):30. PubMed ID: 31159869
[TBL] [Abstract][Full Text] [Related]
40. Immune microenvironment features and efficacy of PD-1/PD-L1 blockade in non-small cell lung cancer patients with EGFR or HER2 exon 20 insertions.
Chen K; Pan G; Cheng G; Zhang F; Xu Y; Huang Z; Fan Y
Thorac Cancer; 2021 Jan; 12(2):218-226. PubMed ID: 33210451
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
